Sarepta Outlines A Fast Path Forward For Its DMD Gene Therapy

Encouraging data testing the gene therapy in just three boys with Duchenne muscular dystrophy has investors jazzed. CEO Doug Ingram said the company will talk to FDA about how to advance the program.